Valion Bio, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Valion Bio, Inc. (VBIO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $1.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-30
- Valion Bio, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $1.70M, a 88.89% increase from fiscal 2024.
- Valion Bio, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $900.00K, a 154.24% increase from fiscal 2023.
- Valion Bio, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $354.00K, a 87.79% decline from fiscal 2022.
- Valion Bio, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $2.90M, a 81.25% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.70M 10-K · filed 2026-03-30 | |
| 2024-12-31 | $900.00K 10-K · filed 2026-03-30 | $900.00 10-K · filed 2025-03-21 |
| 2023-12-31 | $354.00K 10-K · filed 2025-03-21 | |
| 2022-12-31 | $2.90M 10-K · filed 2024-03-25 | |
| 2021-12-31 | $1.60M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |